鍏ㄧ悆鐮斿彂 | 涓浗棣栨锛佸杩堝畞庐鐢ㄤ簬娌荤枟鍎跨浣庣骇鍒剳鑳惰川鐦ら€傚簲鐥囪繘鍏II鏈熶复搴?
7鏈?鏃ワ紝澶嶆槦鍖昏嵂锛?00196.SH锛?2196.HK锛夊甯冿紝鑷富鐮斿彂鐨凪EK1/2閫夋嫨鎬ф姂鍒跺墏澶嶈繄瀹?sup>庐锛堥€氱敤鍚嶏細鑺︽矁缇庢浛灏肩墖锛屼互涓嬬畝绉扳€滆鑽搧鈥濓級鐢ㄤ簬娌荤枟鍎跨浣庣骇鍒剳鑳惰川鐦わ紙pLGG锛夐€傚簲鐥囦簬涓浗澧冨唴锛堜笉鍖呮嫭娓境鍙板湴鍖猴級鍚姩鈪㈡湡涓村簥璇曢獙銆?/span>
鐜嬪叴鍒╁崥澹?/span>
澶嶆槦鍖昏嵂鑱斿腑鎬昏銆佸叏鐞冪爺鍙戜腑蹇僀EO
鎴戜滑闈炲父娆ｅ枩鍦扮湅鍒板杩堝畞庐鐢ㄤ簬娌荤枟鍎跨浣庣骇鍒剳鑳惰川鐦よ繘鍏II鏈熶复搴婄殑鍏抽敭闃舵锛岃繖涓嶄粎鏄腑鍥介涓繘鍏ヨ棰嗗煙鈪㈡湡涓村簥鐨凪EK闈跺悜鑽墿锛屼篃鏄鏄熷尰鑽叏鐞冪爺鍙戠殑鍙堜竴閲岀▼纰戙€傛湭鏉ワ紝澶嶆槦鍖昏嵂鍏ㄧ悆鐮斿彂鍥㈤槦灏嗛珮鏁堟帹杩涗复搴婅繘绋嬶紝灏芥棭璁╂洿澶氭偅鑰呰幏鐩婁簬杩欎竴鍒涙柊鐤楁硶銆?/span>
鍎跨浣庣骇鍒兌璐ㄧ槫锛坧LGG锛夋偅鑰呮槸鎸囦綆绾у埆鑴戣兌璐ㄧ槫涓殑骞撮緞锛?8宀佺殑鍎跨鍜岄潚灏戝勾鎮ｈ€咃紝涓旀墍鎮ｇ柧鐥呬负2021骞翠笘鐣屽崼鐢熺粍缁囷紙WHO锛変腑鏋㈢缁忕郴缁熻偪鐦ゅ垎绫讳腑鎵€鐗规寚鐨勫寘鎷効绔ュ瀷寮ユ极鎬т綆绾у埆鑳惰川鐦ゃ€佸眬闄愭€ф槦褰㈢粏鑳炶兌璐ㄧ槫绛夊湪鍐呯柧鐥呰€呫€俻LGG鏄効绔ユ渶甯歌鐨勪腑鏋㈢缁忕郴缁熻偪鐦わ紝鍗犳墍鏈夊効绔ヤ腑鏋㈢缁忕郴缁熻偪鐦ょ殑40-50%銆?015骞寸編鍥芥柊璇婃柇鐨刾LGG鐥呬緥鏁扮害涓?000~1600渚嬶紝鍦ㄤ腑鍥藉皻鏃犳槑纭殑鍎跨浣庣骇鍒兌璐ㄧ槫鍙戠梾鐜囨姤閬撱€?/span>
鏍规嵁涓€椤瑰涓績銆佸崟鑷傗叀鏈熶复搴婄爺绌舵暟鎹樉绀?/span>[1]锛屽杩堝畞庐娌荤枟BRAF铻嶅悎绐佸彉鎴朆RAF V600E绐佸彉鎴朜F1绐佸彉闃虫€х殑鍎跨浣庣骇鍒剳鑳惰川鐦ゆ偅鑰呯殑瀹㈣缂撹В鐜囷紙ORR锛夎揪鍒颁簡68.2%锛岀柧鐥呮帶鍒剁巼锛圖CR锛夊彲杈?00%锛屽湪鐮旂┒鏈熼棿鏃犳偅鑰呭嚭鐜扮柧鐥呰繘灞曪紝鎵€鏈夋偅鑰呭潎涓嶅悓绋嬪害鑾风泭銆傛涓村簥鐮旂┒缁撴灉鏄剧ず澶嶈繄瀹?sup>庐瀵逛簬BRAF铻嶅悎绐佸彉鎴朆RAF V600E绐佸彉鎴朜F1绐佸彉闃虫€х殑鍎跨浣庣骇鍒兌璐ㄧ槫鍏锋湁鑹ソ鐨勬不鐤楁晥鏋滐紝瀵逛簬鍎跨浣庣骇鍒兌璐ㄧ槫鐨勬不鐤楁彁渚涗簡闈跺悜娌荤枟鐨勯€夋嫨銆傚杩堝畞庐鏈夋湜鏀瑰彉pLGG鐨勭幇鏈夋不鐤楁牸灞€锛岃鏇村鎮ｈ€呰幏鐩娿€?/span>
鎴嚦鐩墠锛屽杩堝畞庐宸蹭簬涓浗澧冨唴涓婂競骞惰幏鎵逛袱椤归€傚簲鐥囷紝鍖呮嫭鐢ㄤ簬娌荤枟鏈楁牸姹夋柉缁嗚優缁勭粐缁嗚優澧炵敓鐥囷紙LCH锛夊拰缁勭粐缁嗚優鑲跨槫鎴愪汉鎮ｈ€咃紱浠ュ強2宀佸強2宀佷互涓婁即鏈夌棁鐘躲€佹棤娉曟墜鏈殑涓涚姸绁炵粡绾ょ淮鐦わ紙PN锛夌殑鈪犲瀷绁炵粡绾ょ淮鐦ょ梾锛圢F1锛夊効绔ュ強闈掑皯骞存偅鑰呫€?/span>
澶嶈繄瀹?sup>庐鐢ㄤ簬娌荤枟鎴愪汉鈪犲瀷绁炵粡绾ょ淮鐦ょ梾銆佸効绔ヤ綆绾у埆鑴戣兌璐ㄧ槫浜庝腑鍥藉鍐呭潎澶勪簬鈪㈡湡涓村簥璇曢獙闃舵锛岃鑽搧鐢ㄤ簬娌荤枟棰呭鍔ㄩ潤鑴夌暩褰€佸効绔ユ湕鏍兼眽鏂粏鑳炵粍缁囩粏鑳炲鐢熺棁浜庝腑鍥藉鍐呭潎澶勪簬鈪℃湡涓村簥璇曢獙闃舵銆傚叾涓紝璇ヨ嵂鍝佺敤浜庢棤娉曟墜鏈垨鏈悗娈嬬暀/澶嶅彂鐨凬F1鐩稿叧鐨勪笡鐘剁缁忕氦缁寸槫鎴愪汉鎮ｈ€呫€佸効绔ユ湕鏍兼眽鏂粍缁囩粏鑳炲鐢熺棁涓ら」閫傚簲鐥囧潎宸茶鍥藉鑽搧鐩戠潱绠＄悊灞€鑽搧瀹¤瘎涓績绾冲叆绐佺牬鎬ф不鐤楄嵂鐗╃▼搴忋€?/span>
[1] 1.Wenbin Li, Ying Mao, Zhuang Kang, et al. A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway activation. ESMO LBA 2023.
